Physician profile
Edward Schuka
NPI 1194712554
$7,087.94
in general payments reported to CMS, 2019-2025
36 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $332 · 2021: $723 · 2022: $784 · 2023: $1,467 · 2024: $1,437 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,507.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,117.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $790.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $711.64 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $497.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.22 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Astellas Pharma US INC | $430.05 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $388.71 | 2019-2025 | |
| Amgen INC. | $341.04 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $277.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $259.21 | 2020-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $257.10 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $218.62 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $196.90 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.87 | 2019-2025 | Xifaxan |
| Edwards Lifesciences Corporation | $133.97 | 2024 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Schuka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.